成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart 0 Sign in  

[ CAS No. 22047-25-2 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 22047-25-2
Chemical Structure| 22047-25-2
Structure of 22047-25-2 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 22047-25-2 ]

Related Doc. of [ 22047-25-2 ]

Alternatived Products of [ 22047-25-2 ]
Product Citations

Product Citations      Expand+

Yuan, Gengyang ; Dhaynaut, Maeva ; Lan, Yu , et al. DOI: PubMed ID:

Abstract: Metabotropic glutamate receptor 2 (mGluR2) is a therapeutic target for several neuropsychiatric disorders. An mGluR2 function in etiology could be unveiled by positron emission tomography (PET). In this regard, 5-(2-fluoro-4-[11C]methoxyphenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-7-carboxamide ([11C]13, [11C]mG2N001), a potent negative allosteric modulator (NAM), was developed to support this endeavor. [11C]13 was synthesized via the O-[11C]methylation of phenol 24 with a high molar activity of 212 ± 76 GBq/μmol (n = 5) and excellent radiochemical purity (>99%). PET imaging of [11C]13 in rats demonstrated its superior brain heterogeneity and reduced accumulation with pretreatment of mGluR2 NAMs, VU6001966 (9) and MNI-137 (26), the extent of which revealed a time-dependent drug effect of the blocking agents. In a nonhuman primate, [11C]13 selectively accumulated in mGluR2-rich regions and resulted in high-contrast brain images. Therefore, [11C]13 is a potential candidate for translational PET imaging of the mGluR2 function.

Purchased from AmBeed: ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;

Hegde, Pooja V. ; Aragaw, Wassihun W. ; Cole, Malcolm S. , et al. DOI: PubMed ID:

Abstract: Tuberculosis (TB) remains a leading cause of infectious disease-related mortality and morbidity. Pyrazinamide (PZA) is a critical component of the first-line TB treatment regimen because of its sterilizing activity against non-replicating Mycobacterium tuberculosis (Mtb), but its mechanism of action has remained enigmatic. PZA is a prodrug converted by pyrazinamidase encoded by pncA within Mtb to the active moiety, pyrazinoic acid (POA) and PZA resistance is caused by loss-of-function mutations to pyrazinamidase. We have recently shown that POA induces targeted protein degradation of the enzyme PanD, a crucial component of the CoA biosynthetic pathway essential in Mtb. Based on the newly identified mechanism of action of POA, along with the crystal structure of PanD bound to POA, we designed several POA analogs using structure for interpretation to improve potency and overcome PZA resistance. We prepared and tested ring and carboxylic acid bioisosteres as well as 3, 5, 6 substitutions on the ring to study the structure activity relationships of the POA scaffold. All the analogs were evaluated for their whole cell antimycobacterial activity, and a few representative mols. were evaluated for their binding affinity, towards PanD, through isothermal titration calorimetry. We report that analogs with ring and carboxylic acid bioisosteres did not significantly enhance the antimicrobial activity, whereas the alkylamino-group substitutions at the 3 and 5 position of POA were found to be up to 5 to 10-fold more potent than POA. Further development and mechanistic anal. of these analogs may lead to a next generation POA analog for treating TB.

Keywords: Tuberculosis ; Pyrazinoic acid ; pyrazinamide

Purchased from AmBeed: ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;

Product Details of [ 22047-25-2 ]

CAS No. :22047-25-2 MDL No. :MFCD00006134
Formula : C6H6N2O Boiling Point : -
Linear Structure Formula :- InChI Key :DBZAKQWXICEWNW-UHFFFAOYSA-N
M.W : 122.12 Pubchem ID :30914
Synonyms :
2-Acetylpyrazine

Calculated chemistry of [ 22047-25-2 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 9
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.17
Num. rotatable bonds : 1
Num. H-bond acceptors : 3.0
Num. H-bond donors : 0.0
Molar Refractivity : 32.23
TPSA : 42.85 ?2

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.9 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.19
Log Po/w (XLOGP3) : 0.2
Log Po/w (WLOGP) : 0.68
Log Po/w (MLOGP) : -1.11
Log Po/w (SILICOS-IT) : 1.19
Consensus Log Po/w : 0.43

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -1.15
Solubility : 8.64 mg/ml ; 0.0707 mol/l
Class : Very soluble
Log S (Ali) : -0.66
Solubility : 26.8 mg/ml ; 0.219 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -1.94
Solubility : 1.4 mg/ml ; 0.0115 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.57

Safety of [ 22047-25-2 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H332-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 22047-25-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 22047-25-2 ]

[ 22047-25-2 ] Synthesis Path-Downstream   1~2

  • 1
  • [ 13925-00-3 ]
  • [ 22047-25-2 ]
YieldReaction ConditionsOperation in experiment
66%Spectr. With tert.-butylhydroperoxide; In water; at 60℃; for 12h; General procedure: A 15?mL RBF was charged with substrate (0.5 mmol),MnOx?N(at)C catalyst (1 mg, pyrolysis at 600 °C) and TBHP (1.5mmol, 65percent in H2O). The flask was then sealed, and the mixturewas heated at 60 °C for 12 h. The reaction was cooled to roomtemperature and diluted with ethyl acetate (4 mL), before beingcentrifuged at 10000 r/min for 1 min to separate the catalyst.The supernatant was removed and the catalyst waswashed with ethyl acetate (5 × 4 mL). The supernatant wassubsequently combined the ethyl acetate wash solutions andevaporated to dryness to give a residue, which was purified byflash column chromatography over silica gel (ethyl acetate/n?hexane = 1:10, v/v).
  • 2
  • [ 22047-25-2 ]
  • [ 186534-02-1 ]
  • C14H14N4O [ No CAS ]
Recommend Products
Same Skeleton Products

Technical Information

Historical Records

Related Functional Groups of
[ 22047-25-2 ]

Ketones

Chemical Structure| 23787-80-6

[ 23787-80-6 ]

1-(3-Methylpyrazin-2-yl)ethanone

Similarity: 0.91

Chemical Structure| 32974-92-8

[ 32974-92-8 ]

1-(3-Ethylpyrazin-2-yl)ethanone

Similarity: 0.91

Chemical Structure| 1122-62-9

[ 1122-62-9 ]

1-(Pyridin-2-yl)ethanone

Similarity: 0.65

Chemical Structure| 61985-25-9

[ 61985-25-9 ]

4-Acetylimidazole

Similarity: 0.63

Chemical Structure| 37398-49-5

[ 37398-49-5 ]

2-Acetylisonicotinonitrile

Similarity: 0.63

Related Parent Nucleus of
[ 22047-25-2 ]

Pyrazines

Chemical Structure| 23787-80-6

[ 23787-80-6 ]

1-(3-Methylpyrazin-2-yl)ethanone

Similarity: 0.91

Chemical Structure| 32974-92-8

[ 32974-92-8 ]

1-(3-Ethylpyrazin-2-yl)ethanone

Similarity: 0.91

Chemical Structure| 36731-41-6

[ 36731-41-6 ]

2-Ethyl-5(6)-methylpyrazine

Similarity: 0.68

Chemical Structure| 13535-07-4

[ 13535-07-4 ]

2-Amino-5-ethylpyrazine

Similarity: 0.65

Chemical Structure| 88625-24-5

[ 88625-24-5 ]

5-Chloropyrazine-2-carbaldehyde

Similarity: 0.65

; ;